Moreover, IL-33-mediated amplification of type 1 immune cells was shown to exacerbate tissue damage during graft-versus-host disease (GVHD)28,29 and contribute to immune dysregulation in systemic inflammatory diseases30. Here, IL33 is linked to graft versus host disease.